title: Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010.
abstract: The 2010 7th International Melanoma Congress sponsored by the Society for Melanoma Research and held in Sydney, Australia, was held together with the International Melanoma and Skin Cancer Centers group and the International Melanoma Pathology Study Group. As a consequence, there were over 900 registrants that included a wide range of clinicians (surgeons, medical oncologists, dermatologists) specialising in the management of melanoma as well as scientists and students carrying out laboratory-based research in melanoma. There was a general consensus that this grouping of clinicians, pathologists and scientists was mutually advantageous and plans are afoot to continue this grouping in future meetings. The meeting was dominated by the advances being made in treatment of melanoma with selective BRAF inhibitors but interest in epithelial mesenchymal transition and phenotypic changes in melanoma was apparent in many of the talks. The authors have attempted to capture many of the new developments in melanoma research but apologize to those speakers and poster presenters who had equally important findings not captured in these summaries.
authors.affiliation: Peter.Hersey@newcastle.edu.au
authors.forename: P
authors.initials: P
authors.lastname: Hersey
authors.forename: K S M
authors.initials: KS
authors.lastname: Smalley
authors.forename: A
authors.initials: A
authors.lastname: Weeraratna
authors.forename: M
authors.initials: M
authors.lastname: Bosenberg
authors.forename: X D
authors.initials: XD
authors.lastname: Zhang
authors.forename: N K
authors.initials: NK
authors.lastname: Haass
authors.forename: E
authors.initials: E
authors.lastname: Paton
authors.forename: G
authors.initials: G
authors.lastname: Mann
authors.forename: R A
authors.initials: RA
authors.lastname: Scolyer
authors.forename: T
authors.initials: T
authors.lastname: Tüting
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology; D009517:New South Wales; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000378:metabolism; D015027:Zebrafish / Q000235:genetics
chemical_list: D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases